Skip to content
You can now search across every topic, entity and event.What's new
UK Startups and Innovation
14JUL

J&J backs Trimtech seed to GBP35.6m

2 min read
08:43UTC

Trimtech Therapeutics extended its seed round to GBP35.6m after Johnson & Johnson Innovation and BGF added $14m and took board seats.

← Back to Britain funds and defunds its own scienceJump to analysis ↓
TechnologyDeveloping
Key takeaway

J&J and BGF bought board seats at Trimtech, backing UK biotech that domestic venture is not funding.

Trimtech Therapeutics, a Cambridge biotech, extended its seed round to GBP35.6m after Johnson & Johnson Innovation (JJDC), the US pharmaceutical group's venture arm, and BGF, a UK growth-capital investor, added $14m and both took board seats 1. The company designs targeted protein degraders, molecules that tag a disease-causing protein for the cell's own disposal system rather than merely blocking it, aimed at neurodegenerative and inflammatory disease.

The extension builds on a GBP25m seed led by Cambridge Innovation Capital in 2025. Strategic pharmaceutical capital, not UK venture, is funding the deep end here.

It is the same pattern as SAP taking a stake in Conduct to hedge its own migration deadline : a corporate investor buys a board seat to watch a technology it may later need, cheaper than building or acquiring it outright. For an early biotech, that visibility cuts both ways, bringing a route to market alongside an incumbent already inside the boardroom.

Deep Analysis

In plain English

Trimtech Therapeutics is a Cambridge company developing medicines that use 'targeted protein degraders', molecules that tag disease-causing proteins so the body's own cells break them down naturally, rather than simply blocking them the way most drugs do. The company has just topped up its earliest funding round to £35.6m after Johnson & Johnson's venture arm and BGF, a UK growth-capital investor, each put in money and took a seat on its board. A board seat gives an investor a formal say in how the company is run, which for a large drugmaker like Johnson & Johnson often signals interest in eventually licensing or buying the technology.

Sources:UKTN
Mentions:Laverock Therapeutics →Johnson & Johnson Innovation (JJDC) →BGF →Cambridge Innovation Capital →Cambridge →Conduct →SAP →Trimtech Therapeutics →
First Reported In

Update #10 · AI takes record 44% as UK equity shrinks

UKTN· 4 Jul 2026
Read original →
Causes and effects
Caused by
Conduct takes $60m as SAP buys in
SAP's strategic stake in Conduct set the template of a corporate investor buying board-seat visibility, now repeated with J&J Innovation and BGF in Trimtech.
Occurred 17 Jun 2026
Read story →
This Event
J&J backs Trimtech seed to GBP35.6m
Corporate pharmaceutical capital, not UK venture, is funding the deep end of British biotech and buying boardroom visibility with it.
Different Perspectives
Institute of Physics
Institute of Physics
The Institute has long argued STFC's national-laboratory infrastructure, not its grant programmes, is the binding constraint on UK physics output, and warns mothballing capacity like Clara removes capability that cannot be rebuilt on a four-year cycle. It represents the discovery-science community absorbing the reallocation the Bank's equity cheques do not touch.
Helsing
Helsing
The Munich-headquartered defence-AI firm chose Plymouth over Continental sites for a £350m manufacturing plant building underwater surveillance gliders, alongside its record raise. Its choice of postcode signals confidence in UK manufacturing capacity for defence hardware even as it looks abroad for the capital financing that hardware.
Dragoneer Investment Group, Lightspeed Venture Partners and Iconiq
Dragoneer Investment Group, Lightspeed Venture Partners and Iconiq
The three US growth-capital firms backed Helsing's $1.8bn round at an $18bn valuation, more than doubling the mark set only a year earlier, with demand reportedly exceeding the capital on offer. Their money, not a UK sovereign vehicle, is what funds the Plymouth plant, extending a pattern of foreign capital underwriting British defence-hardware manufacturing this cycle.
British Business Bank
British Business Bank
The Bank wrote its largest-ever direct life-sciences cheque into Alchemab and added a £6.5bn SME lending guarantee the same week UKRI confirmed the STFC cuts. It is deploying an April mandate change letting it lead venture rounds and invest directly up to £60m per company, treating equity extension rounds and small-business debt as newly within its risk appetite.
Daphni
Daphni
The Paris seed fund joined Speedinvest and three UK backers in Astral Systems' GBP23m Series A for modular fusion reactors, one of the round's five European co-investors betting on lab-to-market fusion ahead of any working commercial reactor. Unlike CuspAI's all-foreign cap table, this round kept a UK lead investor in Mercia Ventures.
EQT
EQT
EQT, appointed by the European Innovation Council to run the EUR5bn Scaleup Europe Fund, entered advanced talks for a further CuspAI stake reported on 3 July, the fund's first pursuit of a UK-founded winner. A closed deal would put EU sovereign capital, not a UK vehicle, on the cap table of a company Britain's own funds passed over.